Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

imPROve-asthma - A Prospective, 24-month, Observational Study to Investigate the Change in Patient-Reported Outcomes in Severe Eosinophilic Asthma Patients Treated With Benralizumab Biologic Therapy Under Real-life Conditions in Germany

NCT04184284 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04184284
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04184284 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
imPROve-asthma - A Prospective, 24-month, Observational Study to Investigate the Change in Patient-Reported Outcomes in Severe Eosinophilic Asthma Patients Treated With Benralizumab Biologic Therapy Under Real-life Conditions in Germany
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
November 15, 2019
Completion date
December 19, 2023
Enrollment
246 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

asthma